Celadon Pharmaceuticals
Plc
("Celadon" or the
"Group")
Investor Site Visit - Tuesday
22nd October 2024
4th
October 2024 - Celadon Pharmaceuticals Plc
(AIM: CEL), a UK-based pharmaceutical company focused on the
research, cultivation, manufacturing, and sale of breakthrough
cannabis-based medicines, is pleased to extend an invitation for
new and existing shareholders to visit our cultivation and
manufacturing facility in the West Midlands on 22 October 2024,
organised by Global Investment Strategy UK Ltd.
James Short, Chief Executive Officer of
Celadon, will take investors on a walkthrough tour of the Group's
100,000 sq ft facility which will be followed up with a
presentation and the opportunity for Q&A. A light lunch and
drinks will be provided.
Further details regarding location and time
will be provided once investors have registered their interest, and
relevant non-disclosure agreements have been signed. To register
your interest for this event please click on the following link and
fill out your details in the form provided; https://celadonpharma.com/investor-site-visit/
Enquiries:
|
|
|
|
Celadon Pharmaceuticals Plc
|
|
|
James Short
Jonathan Turner
|
Via Sodali & Co
|
|
Canaccord Genuity Limited (Nominated Adviser and
Broker)
|
|
|
Bobbie Hilliam / Andrew
Potts
|
+44 (0)20 7523 8000
|
|
|
|
|
Global Investment Strategy UK Limited (Joint
Broker)
James Sheehan
|
+44 (0)20 7048 9400
|
|
Sodali & Co
|
|
|
Elly Williamson / Sam Austrums /
Nick Johnson
|
+44 (0)20 7250 1446
|
|
|
|
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a
UK-based pharmaceutical company focused on
the development, production and sale of breakthrough cannabis-based
medicines. Its primary focus is on
improving quality of life for chronic pain sufferers, as well as
exploring the potential of cannabis-based medicines for other
conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP
approved and comprises indoor hydroponic cultivation, proprietary
GMP extraction and an analytical and R&D laboratory. Celadon's
Home Office licence allows for the commercial supply of its
pharmaceutical-grade cannabis product. The Group owns an approved
clinical trial using cannabis-based medicinal products to treat
chronic pain in the UK. Celadon also has a minority interest in
early-stage biopharma Kingdom Therapeutics, which is developing a
licensed cannabinoid medicine to treat children with Autism
Spectrum Disorder.
For further information please visit
our website www.celadonpharma.com
This announcement contains inside information for the purposes
of article 7 of the Market Abuse Regulation (EU) 596/2014 as
amended by regulation 11 of the Market Abuse (Amendment) (EU Exit)
Regulations 2019/310. With the publication of this announcement,
this information is now considered to be in the public
domain.